- Home
- GMAB vs MAS Comparison
GMAB vs MAS Comparison
Compare GMAB & MAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- MAS
- Stock Information
- Founded
- GMAB 1999
- MAS 1929
- Country
- GMAB Denmark
- MAS United States
- Employees
- GMAB 2638
- MAS N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- MAS Industrial Specialties
- Sector
- GMAB Health Care
- MAS Industrials
- Exchange
- GMAB Nasdaq
- MAS Nasdaq
- Market Cap
- GMAB 13.4B
- MAS 14.2B
- IPO Year
- GMAB N/A
- MAS N/A
- Fundamental
- Price
- GMAB $22.25
- MAS $63.74
- Analyst Decision
- GMAB Buy
- MAS Buy
- Analyst Count
- GMAB 9
- MAS 13
- Target Price
- GMAB $39.17
- MAS $72.65
- AVG Volume (30 Days)
- GMAB 1.3M
- MAS 2.1M
- Earning Date
- GMAB 05-08-2025
- MAS 07-24-2025
- Dividend Yield
- GMAB N/A
- MAS 1.94%
- EPS Growth
- GMAB 276.80
- MAS N/A
- EPS
- GMAB 18.36
- MAS 3.66
- Revenue
- GMAB $3,230,902,140.00
- MAS $7,703,000,000.00
- Revenue This Year
- GMAB $747.74
- MAS N/A
- Revenue Next Year
- GMAB $14.81
- MAS $4.05
- P/E Ratio
- GMAB $1.21
- MAS $17.48
- Revenue Growth
- GMAB 25.43
- MAS N/A
- 52 Week Low
- GMAB $17.24
- MAS $56.55
- 52 Week High
- GMAB $28.56
- MAS $86.70
- Technical
- Relative Strength Index (RSI)
- GMAB 64.68
- MAS 50.82
- Support Level
- GMAB $20.88
- MAS $62.78
- Resistance Level
- GMAB $22.15
- MAS $64.36
- Average True Range (ATR)
- GMAB 0.39
- MAS 1.27
- MACD
- GMAB 0.14
- MAS 0.01
- Stochastic Oscillator
- GMAB 94.62
- MAS 55.28
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware and lighting products.